Two major bills of interest to CLSA have been presented to Governor Brown for his signing or veto: include SB 212 (Jackson) and SB 1121 (Dodd). A third key bill of interest to CLSA, AB 2167 (Chau), died in the Senate during the final week of the legislative session.
On Aug. 29, California’s Office of Statewide Health Planning and Development (OSHPD) held a public hearing regarding proposed regulations to implement Senate Bill 17, which was signed into law last year.
California Life Sciences Association (CLSA) today urged Governor Jerry Brown to sign Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and awaits action by Governor Brown, who has until Sept. 30 to sign or veto the legislation.
CLSA was a proud sponsor and participant of the 6th Annual Rally for Medical Research & National Day of Action on Sept. 13-14, 2018, an annual event that brings together more than 300 organizations to call on our nation’s policymakers to make funding for National Institutes of Health (NIH) a national priority.
On Sept. 11, CLSA co-hosted a multi-state life sciences association Congressional briefing on the patent system and how it works toward encouraging innovation in the development of life saving technologies.
Assembly Bill 375, the California Consumer Privacy Act, will require companies that store large amounts of data, such as Google, Facebook, Twitter, and others, to disclose what kinds of data they collect, and give consumers more control over how that data is shared.
The California Life Sciences Association (CLSA) joined a coalition, which includes fellow life sciences trade associations, providers, insurers, and a number of other key stakeholders, to address the concerns related to HIPAA preemption and clinical trials data in the recently enacted AB 375, “The California Consumer Privacy Act of 2018” (“Privacy Act”), which will become effective January 1, 2020.
August has been a successful month for CLSA in educating the California state legislature on issues of critical importance to the life sciences industry in California.
CLSA’s federal government relations team provides an update on the outlook for key federal life sciences legislation likely to be addressed this year in Congress.
This August, CLSA participated in a medical technology industry roundtable discussion with Congressman Khanna (D-Fremont). Organized by AdvaMed and hosted by BD Biosciences in San Jose, attendees included representatives from CLSA members BD and Roche, and other medtech innovators including Boston Scientific, Elekta, Stryker and Varian.